Preprint · not peer-reviewed Researchers Educators Students Patients & Families

Exome and transcriptome analysis probes schizophrenia in a case with exceptionally low polygenic risk

A bioRxiv preprint applies integrated genomic analysis to a post-mortem schizophrenia case sitting below the first percentile for polygenic risk score, seeking rare variants that may account for liability in the absence of common-variant burden.

Published · AI-drafted summary based on 1 public source
Illustration for generic story
Illustrative image — not from the source article.
Share

Researchers have posted a preprint on bioRxiv describing an integrated exome-sequencing and transcriptome analysis of a single post-mortem schizophrenia case — designated SZ07 — whose schizophrenia polygenic risk score (PRS) fell below the first percentile among ancestry-matched cases. The study asks whether individual-level genomic and transcriptomic analysis can identify rare or novel variants potentially relevant to disease liability when common-variant burden is minimal.

The team applied multiple variant-prediction tools to the exome to generate a prioritised panel of candidate variants and corresponding genes, then cross-referenced these with transcriptomic data from the same individual. The approach illustrates how rare variants of larger effect may contribute to schizophrenia in a subset of individuals who sit at the extreme low end of the polygenic risk distribution — a finding relevant to the broader question of how polygenic and monogenic or oligogenic contributions interact across the liability spectrum.

The work is a single-case study and carries the inherent limitations of post-mortem tissue analysis and N-of-1 design. As a preprint, it has not yet undergone peer review. Researchers in psychiatric genomics and variant interpretation may find the methodological framework — combining exome variant prioritisation with transcriptomic validation — of interest independent of the specific case findings.

Plain-language version

For patients, families, and general readers. Educational only — not medical advice.

Scientists studying schizophrenia — a condition that affects how a person thinks and experiences reality — normally look at hundreds of common genetic differences spread across the genome to estimate how much inherited risk a person carries. This estimate is called a polygenic risk score.

In this study, researchers examined the genetic data from a person who had schizophrenia but had a very low polygenic risk score — meaning the usual common genetic factors explained very little of their illness. By looking more closely at the full set of their genes (their exome) and at which genes were switched on or off in their brain, the team hoped to find rarer genetic changes that might help explain why that person developed the condition.

This is early-stage research on a single case, shared as a preprint — meaning it has not yet been checked by independent scientific reviewers. It does not change how schizophrenia is diagnosed or treated. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary sourcePreprint bioRxiv (Cold Spring Harbor Laboratory) · 2026-11-11
    Integrated exome-transcriptome analysis of a schizophrenia case with an exceptionally low polygenic risk score

Tags

schizophrenia polygenic-risk-score exome-sequencing rare-variants psychiatric-genomics variant-interpretation preprint
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List